Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension

Journal of Hypertension

Volumn 25, Issue 10, 2007, Pages 2168-2177

  Mallion, Jean Michel ^a   Heagerty, Anthony ^b   Laeis, Petra ^c  

^a HÔPITAL MICHALLON   (France)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c Sankyo Pharma GmbH   (Germany)

Author keywords

Efficacy; Elderly; Isolated systolic hypertension; Nitrendipine; Olmesartan medoxomil; Tolerability

Indexed keywords

HYDROCHLOROTHIAZIDE; NITRENDIPINE; OLMESARTAN;

AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; GERIATRIC PATIENT; HUMAN; ISOLATED SYSTOLIC HYPERTENSION; MALE; MULTICENTER STUDY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; VERTIGO;

EID: 34748894914     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328287ad0d     Document Type: Article

References (27)

1. Vokonas PS, Kannel WB, Cupples LA. Epidemiology and risk of hypertension in the elderly: the Framingham Study. J Hypertens 1988; 6 (Suppl 6):S3-S9.
2. Benetos A, Zureik M, Morcet J, Thomas F, Bean K, Safar M, et al. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol 2000; 35:673-680.
3. ESH-ESC. European Society of Hypertension-European Society of Cardiology (ESH-ESC) guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
4. Alli C, Avanzini F, Bettelli G, Colombo F, Torri V, Tognoni G. The long-term prognostic significance of repeated blood pressure measurements in the elderly: SPAA (Studio sulla Pressione Arteriosa nell'Anziano) 10-year follow-up. Arch Intern Med 1999; 159:1205-1212.
5. Staessen J, Amery A, Fagard R. Isolated systolic hypertension in the elderly. J Hypertens 1900; 8:393-405.
6. Neaton JD, Wentworth D, Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316 099 white men. Arch Intern Med 1992; 152:56-64.
7. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, et al., Systolic Hypertension in Europe Trial Investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282:539-546.
8. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program (SHEP). Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results. JAMA 1991; 26: 3255-3264.
9. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al., The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764.
10. Liu L, Wang JG, Gong L, Liu G, Staessen JA, Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16:1823-1829.
11. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355:865-872.
12. Furmaga EM, Murphy CM, Carter BL. Isolated systolic hypertension in older patients. Clin Pharm 1993; 12:347-358.
13. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288:1491-1498.
14. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62:1345-1353.
15. Brunner HR, Laeis P. Clinical efficacy of olmesartan medoxomil. J Hypertens 2003; 21 (Suppl 2):S43-S46.
16. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3:283-291.
17. Chilman-Blair K, Rabasseda X. Olmesartan, an AT1-selective antihypertensive agent. Drugs Today 2003; 39:745-761.
18. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002; 16 (Suppl 2): S24-S28.
19. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens 2001; 19 (Suppl 1): S49-S56.
20. Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17:252-259.
21. Sellin L, Stegbauer J, Laeis P, Rump LC. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005; 23:2083-2092.
22. Ferrara LA, Fasano ML, de Simone G, Soro S, Gagliardi R. Antihypertensive and cardiovascular effects of nitrendipine: a controlled study vs. placebo. Clin Pharmacol Ther 1985; 38:434-438.
23. Palombo C, Marabotti C, Genovesi-Ebert A, Giuliano G, Giaconi S, Fommei E, et al. Long-term hypotensive treatment with nitrendipine in mild to moderate essential hypertension: preliminary results of a placebo-controlled study versus atenolol. J Cardiovasc Pharmacol 1987; 10 (Suppl 10):S90-S95.
24. Lazarus JH, Littley MD, Phillips DI. Efficacy of once daily nitrendipine in essential hypertension - a study using ambulatory blood pressure monitoring. J Hum Hypertens 1988; 2:191-194.
25. Ekbom T, Linjer E, Hedner T, Lanke J, De Faire U, Wester PO, et al. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2. Blood Press 2004; 13:137-141.
26. Rump LC, Sellin L, Laeis P. Evaluation of the additive antihypertensive efficacy of hydrochlorothiazide and olmesartan medoxomil in patients with medoxomil monotherapy. J Hypertens 2004; 22 (Suppl 1):139.
27. Palatini P, Dorigatti F,Mugellini A,Spagnuolo V, Vari N, Ferrara R, Bertocchi F. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study. Clin Ther 2004; 26:1436-1445.